nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—Epirubicin—urinary bladder cancer	0.733	1	CbGbCtD
Fluocinolone Acetonide—NR3C1—urine—urinary bladder cancer	0.00768	0.118	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Raltitrexed—Methotrexate—urinary bladder cancer	0.00636	1	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—prostate gland—urinary bladder cancer	0.00632	0.0969	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—seminal vesicle—urinary bladder cancer	0.00535	0.082	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—smooth muscle tissue—urinary bladder cancer	0.00448	0.0686	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—renal system—urinary bladder cancer	0.00431	0.0661	CbGeAlD
Fluocinolone Acetonide—SERPINA6—renal system—urinary bladder cancer	0.00429	0.0658	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—urethra—urinary bladder cancer	0.00423	0.0649	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—female reproductive system—urinary bladder cancer	0.00345	0.0529	CbGeAlD
Fluocinolone Acetonide—SERPINA6—female reproductive system—urinary bladder cancer	0.00344	0.0527	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—vagina—urinary bladder cancer	0.00312	0.0479	CbGeAlD
Fluocinolone Acetonide—NR3C1—prostate gland—urinary bladder cancer	0.00276	0.0423	CbGeAlD
Fluocinolone Acetonide—NR3C1—seminal vesicle—urinary bladder cancer	0.00233	0.0358	CbGeAlD
Fluocinolone Acetonide—NR3C1—epithelium—urinary bladder cancer	0.00203	0.0311	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—lymph node—urinary bladder cancer	0.00202	0.031	CbGeAlD
Fluocinolone Acetonide—NR3C1—smooth muscle tissue—urinary bladder cancer	0.00195	0.0299	CbGeAlD
Fluocinolone Acetonide—NR3C1—renal system—urinary bladder cancer	0.00188	0.0288	CbGeAlD
Fluocinolone Acetonide—NR3C1—urethra—urinary bladder cancer	0.00185	0.0283	CbGeAlD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—BPTF—urinary bladder cancer	0.00173	0.0562	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—female reproductive system—urinary bladder cancer	0.00151	0.0231	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00148	0.048	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—vagina—urinary bladder cancer	0.00136	0.0209	CbGeAlD
Fluocinolone Acetonide—NR3C1—Signaling events mediated by HDAC Class II—HDAC4—urinary bladder cancer	0.00114	0.0372	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—lymph node—urinary bladder cancer	0.000881	0.0135	CbGeAlD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000787	0.0255	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—KRT5—urinary bladder cancer	0.000783	0.0254	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MT2A—urinary bladder cancer	0.00066	0.0214	CbGpPWpGaD
Fluocinolone Acetonide—Abscess—Doxorubicin—urinary bladder cancer	0.000561	0.00342	CcSEcCtD
Fluocinolone Acetonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.00056	0.0182	CbGpPWpGaD
Fluocinolone Acetonide—Eye disorder—Thiotepa—urinary bladder cancer	0.000559	0.00341	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Mitomycin—urinary bladder cancer	0.000559	0.00341	CcSEcCtD
Fluocinolone Acetonide—Rash pustular—Doxorubicin—urinary bladder cancer	0.000557	0.00339	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Methotrexate—urinary bladder cancer	0.000557	0.00339	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—ESR2—urinary bladder cancer	0.000555	0.018	CbGpPWpGaD
Fluocinolone Acetonide—Infestation—Fluorouracil—urinary bladder cancer	0.000552	0.00336	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Fluorouracil—urinary bladder cancer	0.000552	0.00336	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.000539	0.00329	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Mitomycin—urinary bladder cancer	0.000538	0.00327	CcSEcCtD
Fluocinolone Acetonide—Rash—Mitomycin—urinary bladder cancer	0.000533	0.00325	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Mitomycin—urinary bladder cancer	0.000533	0.00324	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Epirubicin—urinary bladder cancer	0.000531	0.00324	CcSEcCtD
Fluocinolone Acetonide—Headache—Mitomycin—urinary bladder cancer	0.00053	0.00323	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Thiotepa—urinary bladder cancer	0.000529	0.00322	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Thiotepa—urinary bladder cancer	0.000524	0.00319	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Thiotepa—urinary bladder cancer	0.000521	0.00317	CcSEcCtD
Fluocinolone Acetonide—Erythema—Thiotepa—urinary bladder cancer	0.000521	0.00317	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Epirubicin—urinary bladder cancer	0.000521	0.00317	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Epirubicin—urinary bladder cancer	0.000521	0.00317	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Fluorouracil—urinary bladder cancer	0.000517	0.00315	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.000508	0.0165	CbGpPWpGaD
Fluocinolone Acetonide—Rhinitis—Gemcitabine—urinary bladder cancer	0.000505	0.00307	CcSEcCtD
Fluocinolone Acetonide—Back pain—Thiotepa—urinary bladder cancer	0.000504	0.00307	CcSEcCtD
Fluocinolone Acetonide—Nausea—Mitomycin—urinary bladder cancer	0.000502	0.00306	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Fluorouracil—urinary bladder cancer	0.000496	0.00302	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000495	0.00301	CcSEcCtD
Fluocinolone Acetonide—Viral infection—Doxorubicin—urinary bladder cancer	0.000492	0.00299	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Thiotepa—urinary bladder cancer	0.000491	0.00299	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Epirubicin—urinary bladder cancer	0.000486	0.00296	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Doxorubicin—urinary bladder cancer	0.000482	0.00293	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Doxorubicin—urinary bladder cancer	0.000482	0.00293	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Etoposide—urinary bladder cancer	0.000479	0.00292	CcSEcCtD
Fluocinolone Acetonide—Infestation—Etoposide—urinary bladder cancer	0.000479	0.00292	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—PPARG—urinary bladder cancer	0.000475	0.0154	CbGpPWpGaD
Fluocinolone Acetonide—Dermatitis contact—Epirubicin—urinary bladder cancer	0.000474	0.00289	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000466	0.0151	CbGpPWpGaD
Fluocinolone Acetonide—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000461	0.00281	CcSEcCtD
Fluocinolone Acetonide—Cough—Thiotepa—urinary bladder cancer	0.000455	0.00277	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000454	0.00276	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Cisplatin—urinary bladder cancer	0.000452	0.00275	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Doxorubicin—urinary bladder cancer	0.00045	0.00274	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Gemcitabine—urinary bladder cancer	0.000445	0.00271	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Thiotepa—urinary bladder cancer	0.000444	0.0027	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Epirubicin—urinary bladder cancer	0.000443	0.0027	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Doxorubicin—urinary bladder cancer	0.000439	0.00267	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Cisplatin—urinary bladder cancer	0.000439	0.00267	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.000438	0.0142	CbGpPWpGaD
Fluocinolone Acetonide—Erythema—Gemcitabine—urinary bladder cancer	0.000438	0.00267	CcSEcCtD
Fluocinolone Acetonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—urinary bladder cancer	0.000438	0.0142	CbGpPWpGaD
Fluocinolone Acetonide—Alopecia—Fluorouracil—urinary bladder cancer	0.000438	0.00266	CcSEcCtD
Fluocinolone Acetonide—Erythema—Fluorouracil—urinary bladder cancer	0.000431	0.00262	CcSEcCtD
Fluocinolone Acetonide—Back pain—Gemcitabine—urinary bladder cancer	0.000424	0.00258	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000423	0.00258	CcSEcCtD
Fluocinolone Acetonide—Infection—Thiotepa—urinary bladder cancer	0.000423	0.00257	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000417	0.00254	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Cisplatin—urinary bladder cancer	0.000415	0.00253	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000412	0.0134	CbGpPWpGaD
Fluocinolone Acetonide—Dry eye—Doxorubicin—urinary bladder cancer	0.00041	0.0025	CcSEcCtD
Fluocinolone Acetonide—Erythema—Cisplatin—urinary bladder cancer	0.000409	0.00249	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Cisplatin—urinary bladder cancer	0.000409	0.00249	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Fluorouracil—urinary bladder cancer	0.000406	0.00247	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Etoposide—urinary bladder cancer	0.000402	0.00245	CcSEcCtD
Fluocinolone Acetonide—Visual disturbance—Methotrexate—urinary bladder cancer	0.000393	0.00239	CcSEcCtD
Fluocinolone Acetonide—Eczema—Epirubicin—urinary bladder cancer	0.000388	0.00236	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000388	0.00236	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000387	0.00236	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Epirubicin—urinary bladder cancer	0.000386	0.00235	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—ADP signalling through P2Y purinoceptor 1—SRC—urinary bladder cancer	0.000386	0.0125	CbGpPWpGaD
Fluocinolone Acetonide—Vision blurred—Cisplatin—urinary bladder cancer	0.000385	0.00234	CcSEcCtD
Fluocinolone Acetonide—Cough—Gemcitabine—urinary bladder cancer	0.000383	0.00233	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Etoposide—urinary bladder cancer	0.00038	0.00231	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Gemcitabine—urinary bladder cancer	0.000373	0.00227	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—RHOA—urinary bladder cancer	0.000369	0.012	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000367	0.00224	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Etoposide—urinary bladder cancer	0.000367	0.00223	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—urinary bladder cancer	0.000365	0.0118	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Thiotepa—urinary bladder cancer	0.000364	0.00221	CcSEcCtD
Fluocinolone Acetonide—Back pain—Etoposide—urinary bladder cancer	0.000362	0.0022	CcSEcCtD
Fluocinolone Acetonide—Eczema—Doxorubicin—urinary bladder cancer	0.000359	0.00218	CcSEcCtD
Fluocinolone Acetonide—Oedema—Gemcitabine—urinary bladder cancer	0.000358	0.00218	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Doxorubicin—urinary bladder cancer	0.000357	0.00217	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000357	0.00217	CcSEcCtD
Fluocinolone Acetonide—Infection—Gemcitabine—urinary bladder cancer	0.000355	0.00216	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000353	0.0115	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Fluorouracil—urinary bladder cancer	0.000352	0.00214	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000351	0.00214	CcSEcCtD
Fluocinolone Acetonide—Infection—Fluorouracil—urinary bladder cancer	0.000349	0.00213	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Epirubicin—urinary bladder cancer	0.000348	0.00212	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Epirubicin—urinary bladder cancer	0.000348	0.00212	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000345	0.0021	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—ESR1—urinary bladder cancer	0.000337	0.0109	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—urinary bladder cancer	0.000337	0.0109	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Etoposide—urinary bladder cancer	0.000336	0.00205	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Thiotepa—urinary bladder cancer	0.000336	0.00205	CcSEcCtD
Fluocinolone Acetonide—Oedema—Cisplatin—urinary bladder cancer	0.000333	0.00203	CcSEcCtD
Fluocinolone Acetonide—Infection—Cisplatin—urinary bladder cancer	0.000331	0.00202	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.00033	0.00201	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000327	0.00199	CcSEcCtD
Fluocinolone Acetonide—Cough—Etoposide—urinary bladder cancer	0.000327	0.00199	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000326	0.00198	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signal amplification—SRC—urinary bladder cancer	0.000325	0.0105	CbGpPWpGaD
Fluocinolone Acetonide—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000322	0.00196	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Doxorubicin—urinary bladder cancer	0.000322	0.00196	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00032	0.00195	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Circadian Clock—NCOR1—urinary bladder cancer	0.000319	0.0103	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000313	0.00191	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000312	0.0019	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000309	0.00188	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—PPARG—urinary bladder cancer	0.000307	0.00997	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Gemcitabine—urinary bladder cancer	0.000306	0.00186	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000304	0.00185	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000304	0.00185	CcSEcCtD
Fluocinolone Acetonide—Infection—Etoposide—urinary bladder cancer	0.000303	0.00185	CcSEcCtD
Fluocinolone Acetonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—urinary bladder cancer	0.000301	0.00978	CbGpPWpGaD
Fluocinolone Acetonide—Influenza—Epirubicin—urinary bladder cancer	0.000301	0.00183	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Thiotepa—urinary bladder cancer	0.000301	0.00183	CcSEcCtD
Fluocinolone Acetonide—Pain—Fluorouracil—urinary bladder cancer	0.000301	0.00183	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000299	0.00182	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000291	0.00177	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000288	0.00176	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000288	0.00175	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Methotrexate—urinary bladder cancer	0.000287	0.00175	CcSEcCtD
Fluocinolone Acetonide—Infestation—Methotrexate—urinary bladder cancer	0.000287	0.00175	CcSEcCtD
Fluocinolone Acetonide—Pain—Cisplatin—urinary bladder cancer	0.000285	0.00174	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000283	0.00172	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Thiotepa—urinary bladder cancer	0.000281	0.00171	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00028	0.0017	CcSEcCtD
Fluocinolone Acetonide—Influenza—Doxorubicin—urinary bladder cancer	0.000279	0.0017	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000278	0.00169	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000274	0.0089	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—MYC—urinary bladder cancer	0.00027	0.00878	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Thiotepa—urinary bladder cancer	0.00027	0.00165	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—SRC—urinary bladder cancer	0.00027	0.00878	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000269	0.00874	CbGpPWpGaD
Fluocinolone Acetonide—Infestation—Epirubicin—urinary bladder cancer	0.000268	0.00163	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Epirubicin—urinary bladder cancer	0.000268	0.00163	CcSEcCtD
Fluocinolone Acetonide—Rash—Thiotepa—urinary bladder cancer	0.000268	0.00163	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Thiotepa—urinary bladder cancer	0.000268	0.00163	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000268	0.00869	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Thiotepa—urinary bladder cancer	0.000266	0.00162	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.000266	0.00863	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000264	0.00161	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Cisplatin—urinary bladder cancer	0.000264	0.00161	CcSEcCtD
Fluocinolone Acetonide—Pain—Etoposide—urinary bladder cancer	0.000261	0.00159	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000259	0.00158	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000259	0.00158	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Gemcitabine—urinary bladder cancer	0.000253	0.00154	CcSEcCtD
Fluocinolone Acetonide—Nausea—Thiotepa—urinary bladder cancer	0.000253	0.00154	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—TNF—urinary bladder cancer	0.000252	0.0082	CbGpPWpGaD
Fluocinolone Acetonide—Sinusitis—Epirubicin—urinary bladder cancer	0.000252	0.00153	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Endothelins—RHOA—urinary bladder cancer	0.000252	0.00817	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Fluorouracil—urinary bladder cancer	0.000249	0.00152	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000248	0.00151	CcSEcCtD
Fluocinolone Acetonide—Infestation—Doxorubicin—urinary bladder cancer	0.000248	0.00151	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Methotrexate—urinary bladder cancer	0.000248	0.00151	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000246	0.0015	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000245	0.00149	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.000243	0.00788	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—RHOA—urinary bladder cancer	0.000242	0.00787	CbGpPWpGaD
Fluocinolone Acetonide—Rhinitis—Epirubicin—urinary bladder cancer	0.000242	0.00147	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Etoposide—urinary bladder cancer	0.000241	0.00147	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Methotrexate—urinary bladder cancer	0.000241	0.00147	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000241	0.00147	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000237	0.00144	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.000234	0.00759	CbGpPWpGaD
Fluocinolone Acetonide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000233	0.00142	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Fluorouracil—urinary bladder cancer	0.000233	0.00142	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Epirubicin—urinary bladder cancer	0.000232	0.00141	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000232	0.00141	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000228	0.00139	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Methotrexate—urinary bladder cancer	0.000228	0.00139	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Gemcitabine—urinary bladder cancer	0.000227	0.00139	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.000226	0.00734	CbGpPWpGaD
Fluocinolone Acetonide—Mental disorder—Methotrexate—urinary bladder cancer	0.000226	0.00137	CcSEcCtD
Fluocinolone Acetonide—Rash—Gemcitabine—urinary bladder cancer	0.000226	0.00137	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000225	0.00137	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Epirubicin—urinary bladder cancer	0.000225	0.00137	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000225	0.00137	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Methotrexate—urinary bladder cancer	0.000224	0.00137	CcSEcCtD
Fluocinolone Acetonide—Erythema—Methotrexate—urinary bladder cancer	0.000224	0.00137	CcSEcCtD
Fluocinolone Acetonide—Headache—Gemcitabine—urinary bladder cancer	0.000224	0.00136	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Fluorouracil—urinary bladder cancer	0.000224	0.00136	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000224	0.00136	CcSEcCtD
Fluocinolone Acetonide—Rash—Fluorouracil—urinary bladder cancer	0.000222	0.00135	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000222	0.00135	CcSEcCtD
Fluocinolone Acetonide—Headache—Fluorouracil—urinary bladder cancer	0.00022	0.00134	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Methotrexate—urinary bladder cancer	0.00022	0.00134	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Circadian Clock—CREBBP—urinary bladder cancer	0.000219	0.00712	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—PLAU—urinary bladder cancer	0.000219	0.00712	CbGpPWpGaD
Fluocinolone Acetonide—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000219	0.00133	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000217	0.00132	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000217	0.00704	CbGpPWpGaD
Fluocinolone Acetonide—Back pain—Methotrexate—urinary bladder cancer	0.000217	0.00132	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Etoposide—urinary bladder cancer	0.000216	0.00132	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000215	0.007	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000215	0.00131	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Epirubicin—urinary bladder cancer	0.000213	0.0013	CcSEcCtD
Fluocinolone Acetonide—Nausea—Gemcitabine—urinary bladder cancer	0.000213	0.00129	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—urinary bladder cancer	0.000212	0.00689	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Cisplatin—urinary bladder cancer	0.000212	0.00129	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000211	0.00686	CbGpPWpGaD
Fluocinolone Acetonide—Vision blurred—Methotrexate—urinary bladder cancer	0.000211	0.00129	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Epirubicin—urinary bladder cancer	0.000211	0.00129	CcSEcCtD
Fluocinolone Acetonide—Rash—Cisplatin—urinary bladder cancer	0.00021	0.00128	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Cisplatin—urinary bladder cancer	0.00021	0.00128	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Epirubicin—urinary bladder cancer	0.00021	0.00128	CcSEcCtD
Fluocinolone Acetonide—Erythema—Epirubicin—urinary bladder cancer	0.00021	0.00128	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Etoposide—urinary bladder cancer	0.000209	0.00127	CcSEcCtD
Fluocinolone Acetonide—Nausea—Fluorouracil—urinary bladder cancer	0.000209	0.00127	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000208	0.00127	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.000206	0.0067	CbGpPWpGaD
Fluocinolone Acetonide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000205	0.00125	CcSEcCtD
Fluocinolone Acetonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—urinary bladder cancer	0.000205	0.00666	CbGpPWpGaD
Fluocinolone Acetonide—Back pain—Epirubicin—urinary bladder cancer	0.000203	0.00124	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Etoposide—urinary bladder cancer	0.000202	0.00123	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Methotrexate—urinary bladder cancer	0.000201	0.00123	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000201	0.00122	CcSEcCtD
Fluocinolone Acetonide—Nausea—Cisplatin—urinary bladder cancer	0.000198	0.00121	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Epirubicin—urinary bladder cancer	0.000198	0.0012	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Doxorubicin—urinary bladder cancer	0.000197	0.0012	CcSEcCtD
Fluocinolone Acetonide—Cough—Methotrexate—urinary bladder cancer	0.000196	0.00119	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Doxorubicin—urinary bladder cancer	0.000195	0.00119	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Etoposide—urinary bladder cancer	0.000194	0.00118	CcSEcCtD
Fluocinolone Acetonide—Erythema—Doxorubicin—urinary bladder cancer	0.000194	0.00118	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Doxorubicin—urinary bladder cancer	0.000194	0.00118	CcSEcCtD
Fluocinolone Acetonide—Rash—Etoposide—urinary bladder cancer	0.000193	0.00117	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MMP9—urinary bladder cancer	0.000193	0.00625	CbGpPWpGaD
Fluocinolone Acetonide—Dermatitis—Etoposide—urinary bladder cancer	0.000192	0.00117	CcSEcCtD
Fluocinolone Acetonide—Headache—Etoposide—urinary bladder cancer	0.000191	0.00117	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Methotrexate—urinary bladder cancer	0.000191	0.00116	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—HRAS—urinary bladder cancer	0.00019	0.00618	CbGpPWpGaD
Fluocinolone Acetonide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00019	0.00116	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Epirubicin—urinary bladder cancer	0.000189	0.00115	CcSEcCtD
Fluocinolone Acetonide—Back pain—Doxorubicin—urinary bladder cancer	0.000188	0.00114	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.000184	0.00599	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—SRC—urinary bladder cancer	0.000184	0.00598	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.000184	0.00596	CbGpPWpGaD
Fluocinolone Acetonide—Cough—Epirubicin—urinary bladder cancer	0.000183	0.00111	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Doxorubicin—urinary bladder cancer	0.000183	0.00111	CcSEcCtD
Fluocinolone Acetonide—Infection—Methotrexate—urinary bladder cancer	0.000182	0.00111	CcSEcCtD
Fluocinolone Acetonide—Nausea—Etoposide—urinary bladder cancer	0.000181	0.0011	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000179	0.00109	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000179	0.00582	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Epirubicin—urinary bladder cancer	0.000179	0.00109	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—SRC—urinary bladder cancer	0.000177	0.00576	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Doxorubicin—urinary bladder cancer	0.000174	0.00106	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000171	0.00556	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Epirubicin—urinary bladder cancer	0.000171	0.00104	CcSEcCtD
Fluocinolone Acetonide—Infection—Epirubicin—urinary bladder cancer	0.00017	0.00104	CcSEcCtD
Fluocinolone Acetonide—Cough—Doxorubicin—urinary bladder cancer	0.000169	0.00103	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000168	0.00546	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000168	0.00102	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000167	0.00102	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000165	0.00101	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000161	0.00523	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.00016	0.0052	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.000159	0.00517	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Doxorubicin—urinary bladder cancer	0.000158	0.000965	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000158	0.00514	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000158	0.000962	CcSEcCtD
Fluocinolone Acetonide—Infection—Doxorubicin—urinary bladder cancer	0.000157	0.000959	CcSEcCtD
Fluocinolone Acetonide—Pain—Methotrexate—urinary bladder cancer	0.000156	0.000953	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000156	0.00095	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—EGFR—urinary bladder cancer	0.000156	0.00505	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000155	0.000946	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000154	0.005	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.00015	0.00486	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.000149	0.00485	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000149	0.00484	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000148	0.0009	CcSEcCtD
Fluocinolone Acetonide—Pain—Epirubicin—urinary bladder cancer	0.000146	0.000892	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—RHOA—urinary bladder cancer	0.000145	0.00472	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000145	0.000881	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000144	0.000879	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000144	0.00466	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.000144	0.00466	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000137	0.00446	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000137	0.000833	CcSEcCtD
Fluocinolone Acetonide—Pain—Doxorubicin—urinary bladder cancer	0.000135	0.000825	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000135	0.000824	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000135	0.000821	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000134	0.00435	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—urinary bladder cancer	0.000133	0.00432	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000132	0.00428	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000131	0.00426	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000131	0.00424	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.00013	0.00422	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—HRAS—urinary bladder cancer	0.00013	0.00421	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Methotrexate—urinary bladder cancer	0.000129	0.000788	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.000129	0.00419	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.000127	0.00411	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000126	0.000768	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000125	0.000763	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000125	0.000762	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	0.000123	0.004	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Epirubicin—urinary bladder cancer	0.000121	0.000738	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Methotrexate—urinary bladder cancer	0.000121	0.000737	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	0.000121	0.00393	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTZ1—urinary bladder cancer	0.000121	0.00392	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000117	0.000713	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000117	0.000711	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Methotrexate—urinary bladder cancer	0.000116	0.000708	CcSEcCtD
Fluocinolone Acetonide—Rash—Methotrexate—urinary bladder cancer	0.000115	0.000703	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Methotrexate—urinary bladder cancer	0.000115	0.000702	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.000115	0.00374	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—PTEN—urinary bladder cancer	0.000115	0.00373	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	0.000115	0.00373	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Methotrexate—urinary bladder cancer	0.000115	0.000698	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000115	0.00372	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTO2—urinary bladder cancer	0.000114	0.00371	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NAT1—urinary bladder cancer	0.000114	0.00371	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	0.000114	0.0037	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Epirubicin—urinary bladder cancer	0.000113	0.00069	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000113	0.00367	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000112	0.00365	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Doxorubicin—urinary bladder cancer	0.000112	0.000683	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—RB1—urinary bladder cancer	0.00011	0.00357	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.00011	0.00356	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	0.000109	0.00353	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Epirubicin—urinary bladder cancer	0.000109	0.000663	CcSEcCtD
Fluocinolone Acetonide—Nausea—Methotrexate—urinary bladder cancer	0.000109	0.000662	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	0.000109	0.00352	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000108	0.00066	CcSEcCtD
Fluocinolone Acetonide—Rash—Epirubicin—urinary bladder cancer	0.000108	0.000657	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Epirubicin—urinary bladder cancer	0.000108	0.000657	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.000107	0.00349	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Epirubicin—urinary bladder cancer	0.000107	0.000653	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—SRC—urinary bladder cancer	0.000106	0.00346	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—PTEN—urinary bladder cancer	0.000106	0.00344	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Doxorubicin—urinary bladder cancer	0.000105	0.000638	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—UGT2B7—urinary bladder cancer	0.000105	0.00339	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Epirubicin—urinary bladder cancer	0.000102	0.000619	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Doxorubicin—urinary bladder cancer	0.000101	0.000613	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.000101	0.00327	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Doxorubicin—urinary bladder cancer	9.99e-05	0.000608	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Doxorubicin—urinary bladder cancer	9.98e-05	0.000608	CcSEcCtD
Fluocinolone Acetonide—Headache—Doxorubicin—urinary bladder cancer	9.93e-05	0.000604	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	9.59e-05	0.00311	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	9.55e-05	0.0031	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MYC—urinary bladder cancer	9.54e-05	0.0031	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	9.53e-05	0.00309	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP4B1—urinary bladder cancer	9.42e-05	0.00306	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Doxorubicin—urinary bladder cancer	9.41e-05	0.000573	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	9.38e-05	0.00304	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	9.22e-05	0.00299	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IFNA2—urinary bladder cancer	8.97e-05	0.00291	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—SLC19A1—urinary bladder cancer	8.89e-05	0.00289	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	8.82e-05	0.00286	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—KRAS—urinary bladder cancer	8.82e-05	0.00286	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PRSS3—urinary bladder cancer	8.66e-05	0.00281	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	8.47e-05	0.00275	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	8.2e-05	0.00266	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	8.18e-05	0.00266	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	7.89e-05	0.00256	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	7.8e-05	0.00253	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	7.77e-05	0.00252	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	7.74e-05	0.00251	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	7.59e-05	0.00246	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	7.57e-05	0.00246	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	7.57e-05	0.00246	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—HRAS—urinary bladder cancer	7.49e-05	0.00243	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.95e-05	0.00226	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TYMP—urinary bladder cancer	6.93e-05	0.00225	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HDAC4—urinary bladder cancer	6.91e-05	0.00224	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	6.8e-05	0.00221	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	6.75e-05	0.00219	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.65e-05	0.00216	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	6.65e-05	0.00216	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	6.49e-05	0.00211	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PLAU—urinary bladder cancer	6.37e-05	0.00207	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	6.33e-05	0.00206	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	6.28e-05	0.00204	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NAT2—urinary bladder cancer	6.26e-05	0.00203	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TNF—urinary bladder cancer	6.1e-05	0.00198	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	5.85e-05	0.0019	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GLI1—urinary bladder cancer	5.79e-05	0.00188	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	5.58e-05	0.00181	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—RRM2—urinary bladder cancer	5.41e-05	0.00176	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	5.27e-05	0.00171	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CREBBP—urinary bladder cancer	5.25e-05	0.00171	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IGF1—urinary bladder cancer	5.19e-05	0.00168	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ENO2—urinary bladder cancer	5.01e-05	0.00163	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—HPGDS—urinary bladder cancer	5.01e-05	0.00163	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.98e-05	0.00162	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTT1—urinary bladder cancer	4.86e-05	0.00158	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.78e-05	0.00155	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—RHOA—urinary bladder cancer	4.75e-05	0.00154	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	4.59e-05	0.00149	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	4.19e-05	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	4.18e-05	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NQO1—urinary bladder cancer	4.04e-05	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	4.03e-05	0.00131	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IL2—urinary bladder cancer	3.99e-05	0.00129	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—RBX1—urinary bladder cancer	3.97e-05	0.00129	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.92e-05	0.00127	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TSC1—urinary bladder cancer	3.73e-05	0.00121	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ESR2—urinary bladder cancer	3.65e-05	0.00118	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—EP300—urinary bladder cancer	3.58e-05	0.00116	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—JAG1—urinary bladder cancer	3.55e-05	0.00115	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SRC—urinary bladder cancer	3.48e-05	0.00113	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.42e-05	0.00111	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTP1—urinary bladder cancer	3.37e-05	0.00109	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.26e-05	0.00106	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TYMS—urinary bladder cancer	3.13e-05	0.00102	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NCOR1—urinary bladder cancer	3.09e-05	0.001	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTM1—urinary bladder cancer	3.09e-05	0.001	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GPX1—urinary bladder cancer	2.96e-05	0.000962	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ERCC2—urinary bladder cancer	2.91e-05	0.000944	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—KRAS—urinary bladder cancer	2.88e-05	0.000935	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—S100B—urinary bladder cancer	2.88e-05	0.000934	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	2.82e-05	0.000914	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—MTHFR—urinary bladder cancer	2.73e-05	0.000888	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—RHOA—urinary bladder cancer	2.73e-05	0.000885	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	2.65e-05	0.000859	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NCOR1—urinary bladder cancer	2.59e-05	0.00084	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TP53—urinary bladder cancer	2.56e-05	0.000831	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—HRAS—urinary bladder cancer	2.45e-05	0.000795	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.39e-05	0.000777	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	2.39e-05	0.000776	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL2—urinary bladder cancer	2.29e-05	0.000743	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TERT—urinary bladder cancer	2.28e-05	0.00074	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PPARG—urinary bladder cancer	2.22e-05	0.00072	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ESR1—urinary bladder cancer	2.21e-05	0.000718	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CREBBP—urinary bladder cancer	2.13e-05	0.000691	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—FGFR3—urinary bladder cancer	2.09e-05	0.000679	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ESR1—urinary bladder cancer	2.03e-05	0.00066	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PPARG—urinary bladder cancer	2.02e-05	0.000655	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	1.94e-05	0.000629	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CREBBP—urinary bladder cancer	1.78e-05	0.000578	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IGF1—urinary bladder cancer	1.76e-05	0.000571	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—EGFR—urinary bladder cancer	1.75e-05	0.000568	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTGS2—urinary bladder cancer	1.74e-05	0.000566	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—KRAS—urinary bladder cancer	1.65e-05	0.000537	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—RHOA—urinary bladder cancer	1.61e-05	0.000523	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTEN—urinary bladder cancer	1.52e-05	0.000494	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ERBB2—urinary bladder cancer	1.49e-05	0.000484	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—EP300—urinary bladder cancer	1.45e-05	0.000471	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CXCL8—urinary bladder cancer	1.41e-05	0.000459	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—HRAS—urinary bladder cancer	1.41e-05	0.000456	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL2—urinary bladder cancer	1.35e-05	0.000439	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CCND1—urinary bladder cancer	1.32e-05	0.000428	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MMP9—urinary bladder cancer	1.28e-05	0.000415	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.27e-05	0.000414	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTEN—urinary bladder cancer	1.27e-05	0.000413	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EP300—urinary bladder cancer	1.21e-05	0.000394	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SRC—urinary bladder cancer	1.18e-05	0.000383	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MYC—urinary bladder cancer	1.15e-05	0.000373	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MYC—urinary bladder cancer	1.06e-05	0.000343	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EGFR—urinary bladder cancer	1.03e-05	0.000336	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KRAS—urinary bladder cancer	9.77e-06	0.000317	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TP53—urinary bladder cancer	8.68e-06	0.000282	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—HRAS—urinary bladder cancer	8.3e-06	0.00027	CbGpPWpGaD
